Flumequine Sodium

  • CAS:42835-25-6
  • MF:C14H12FNO3
  • Purity:99%
  • Molecular Weight:261.253
Get the best price

Product Details

  • CAS: 42835-25-6
  • MF: C14H12FNO3
  • Appearance: white to off-white powder
  • Quality manufacturer supply Flumequine Sodium 42835-25-6 in stock with high standard

    • Molecular Formula:C14H12FNO3
    • Molecular Weight:261.253
    • Appearance/Colour:white to off-white powder 
    • Vapor Pressure:1.66E-08mmHg at 25°C 
    • Melting Point:253- 255 °C 
    • Refractive Index:1.645 
    • Boiling Point:439.7 °C at 760 mmHg 
    • PKA:pKa 6.42(H2O t=25.0 I=0.025)(Approximate) 
    • Flash Point:219.7 °C 
    • PSA:59.30000 
    • Density:1.45 g/cm3 
    • LogP:2.34600 

    Flumequine(Cas 42835-25-6) Usage

    Preparation

    Synthesis: Condensation of 5-fluoro-2-methyltetrahydroquinoline with diethyl ethoxy-methylenemalonate followed by thermal cycli- zation gives ethyl 6,7-dihydro-9-fluoro-5-meth-yl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-car-boxylate,which is saponified with sodium hydroxide to give flumequine.

    Manufacturing Process

    6-Fluoro-2-methyltetrahydroquinoline (32.2 g, 0.2 mol) is mixed with diethyl ethoxymethylenemalonate, and the mixture is heated at 125°C to 130°C for 3 hours. Polyphosphoric acid (200 g) is added, and the solution is gradually heated to 115°C to 120°C in an oil bath with occasional stirring. The temperature is maintained for 1 hour, then the mixture is poured into 600 ml of water and neutralized with 40% sodium hydroxide solution. The product ester which precipitates is separated by filtration, washed with water and suspended in 2 liters of 10% sodium hydroxide solution. The mixture is heated on the steam bath for 1 hour, treated with decolorizing charcoal, filtered, then neutralized with concentrated hydrochloric acid. The solid product is isolated by filtration of the hot solution, washed with water and recrystallized from dimethylformamide.

    Therapeutic Function

    Antibacterial

    Pharmaceutical Applications

    A tricyclic fluorinated 4-quinolone, with activity similar to that of nalidixic acid in vitro, although it is somewhat more active against some Enterobacteriaceae. Following escalating oral doses of 400, 800 or 1200 mg, mean peak plasma levels reached at 2 h are 13.5, 23.8 and 31.9 mg/L, respectively. The apparent elimination half-life is about 7 h. The main metabolite, hydroxyflumequine, is much more rapidly eliminated. About 60% of a dose appears in the urine, mostly in the form of conjugates. Urinary concentrations following an 800 mg dose are 10–35 mg/L, with a peak of 105 mg/L. It has no effect on the pharmacokinetics of theophylline.Flumequine is generally well tolerated, side effects being mainly mild gastrointestinal tract disturbances, rashes, dizziness and confusion.It is principally used in uncomplicated urinary tract infections.

    Definition

    ChEBI: Flumequine is a member of the class of pyridoquinolines that is 1-oxo-6,7-dihydro-1H,5H-pyrido[3,2,1-ij]quinoline carrying additional carboxy, methyl and fluoro substituents at positions 2, 5 and 9 respectively. It is a pyridoquinoline, a 3-oxo monocarboxylic acid, an organofluorine compound and a quinolone antibiotic.

    InChI:InChI=1/C14H12FNO3/c1-7-2-3-8-4-9(15)5-10-12(8)16(7)6-11(13(10)17)14(18)19/h4-7H,2-3H2,1H3,(H,18,19)

    42835-25-6 Relevant articles

    Selective Catalytic Hydrogenation of Heteroarenes with N-Graphene-Modified Cobalt Nanoparticles (Co3O4-Co/NGratα-Al2O3)

    Chen, Feng,Surkus, Annette-Enrica,He, Lin,Pohl, Marga-Martina,Radnik, J?rg,Topf, Christoph,Junge, Kathrin,Beller, Matthias

    , p. 11718 - 11724 (2015/09/28)

    Cobalt oxide/cobalt-based nanoparticles ...

    Synthesis, absolute configuration and intermediates of 9-fluoro- 6,7- dihydro-5-methyl-1-oxo-1H,5H-benzo[i.j]quinolizine-2-carboxylic acid (flumequine)

    Balint, Jozsef,Egri, Gabriella,Fogassy, Elemer,Boecskei, Zsolt,Simon, Kalman,Gajary, Antal,Friesz, Antal

    , p. 1079 - 1087 (2007/10/03)

    The antibacterial agent 9-fluoro-6,7-dih...

    Process for the synthesis of a benzo [ij] quinolizine-2-carboxylic acid derivative

    -

    , (2008/06/13)

    Process for preparing 6,7-dihydro-9-fluo...

    Process for 6,7-dihydro-9-fluoro-5-methyl-1-oxo-1H,5H-benzo(ij)quinolizine-2-carboxylic acid

    -

    , (2008/06/13)

    An improved process for preparing the an...

    42835-25-6 Process route

    6-fluoro-1,2,3,4-tetrahydro-2-methylquinoline
    42835-89-2

    6-fluoro-1,2,3,4-tetrahydro-2-methylquinoline

    diethyl 2-ethoxymethylenemalonate
    87-13-8

    diethyl 2-ethoxymethylenemalonate

    flumequine
    42835-25-6,202349-45-9

    flumequine

    Conditions
    Conditions Yield
    With PPA; In water; toluene;
    In sodium hydroxide; toluene;
    With PPA; In water; toluene;
    In sodium hydroxide; toluene;
    5-[1-(6-fluoro-2-methyl-1,2,3,4-tetrahydroquinolyl)]-methylene-2,2-dimethyl-1,3-dioxan-4,6-dione
    123400-74-8

    5-[1-(6-fluoro-2-methyl-1,2,3,4-tetrahydroquinolyl)]-methylene-2,2-dimethyl-1,3-dioxan-4,6-dione

    flumequine
    42835-25-6,202349-45-9

    flumequine

    Conditions
    Conditions Yield
    With sodium hydroxide; PPA; In 5,5-dimethyl-1,3-cyclohexadiene;

    42835-25-6 Upstream products

    • 42835-47-2
      42835-47-2

      9-fluoro-5-methyl-1-oxo-6,7-dihydro-1H,5H-pyrido[3,2,1-ij]quinoline-2-carboxylic acid ethyl ester

    • 42835-89-2
      42835-89-2

      6-fluoro-1,2,3,4-tetrahydro-2-methylquinoline

    • 105450-09-7
      105450-09-7

      Diethyl (2-methyl-6-fluorotetrahydro-quinolin-1-yl)methylenemalonate

    • 87-13-8
      87-13-8

      diethyl 2-ethoxymethylenemalonate

    42835-25-6 Downstream products

    • 215178-95-3
      215178-95-3

      R-(+)-flumequine

    • 202349-45-9
      202349-45-9

      S-(-)-flumequine

    • 42835-47-2
      42835-47-2

      9-fluoro-5-methyl-1-oxo-6,7-dihydro-1H,5H-pyrido[3,2,1-ij]quinoline-2-carboxylic acid ethyl ester

    Antioxidant BHT 264

    CAS:128-37-0

    Purity:99%

    Contact Now

    We will contact you as soon as possible


    提交